Clinical Trial Update: Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma [EARLY_Phase 1]

View source ↗

Summary

This document reports an ongoing early-phase neoadjuvant trial of pembrolizumab and lenvatinib for renal cell carcinoma, with patient recruitment currently ongo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Renal Cell Carcinoma | EARLY_Phase 1 | Status: RECRUITING